Problem

The lipolysis-stimulated lipoprotein receptor (LSR) is a promising target for cancer therapy. LSR is overexpressed in many tumor tissues with metastatic signatures such as breast, gastric, and endometrial cancer. LSR expression levels may serve as prognostic indicators and help stratify patients for targeted therapies. The challenge lies in designing a targeted therapy for LSR+ cancers that can be effectively combined with other treatment modalities to enhance therapeutic outcomes.

Solution

• Researchers at OSU have developed a new anti-human LSR monoclonal antibody that showed high surface specificity, binding rate, and internalization in LSR+ TNBCs
• The anti-LSR mAb has been conjugated with potent cytotoxic chemotherapy to create an antibody-drug conjugate (ADC) for specific treatment of LSR+ cancers
• The anti-LSR ADC showed high in vitro anti-TNBC cytotoxicity and in vivo anti-tumor efficacy in TNBC xenografted mouse models

Applications

• Targeted treatment of LSR+ tumors, especially TNBC
• Combination therapy with drugs targeting other surface receptors to address heterogenous tumors containing both LSR- and LSR+ cells
• Development of dual-payload ADCs that conjugate the anti-LSR mAb with multiple drugs, such as a highly potent chemotherapy and an immune boosting reagent

Advantages

• Specific targeting: The anti-LSR mAb demonstrated great surface specificity, high binding rate, and effective internalization in LSR+ cells only
• Reduced toxicity: The technology showed minimal immunogenicity and selectively targeted LSR+ cells effectively delivering a chemotherapy payload with minimal off-target effects
• Improved stability: The engineered anti-LSR mAb and ADCs showed high circulation stability and elevated antibody effector function

Seeking opportunities for co-development, out-licensing or new venture formation